Business Context and Reporting Period
This Form 8-K, filed on February 7, 2021, reports that ARYA Sciences Acquisition Corp III ("ARYA") has entered into a definitive Business Combination Agreement with Nautilus Biotechnology, Inc. ("Nautilus"). The transaction involves a merger where ARYA will domesticate as a Delaware corporation, change its name to "Nautilus Biotechnology, Inc.," and merge with Nautilus. The combined entity is expected to close in the second quarter of 2021, subject to shareholder approvals and other customary conditions.
Key Financial Metrics and Transaction Terms
- Implied Equity Value: The transaction values Nautilus at an implied equity value of $900 million.
- PIPE Financing: ARYA secured $200 million in gross proceeds from a private investment in public equity (PIPE) financing, involving the sale of 20,000,000 shares at $10.00 per share.
- Minimum Cash Proceeds: A closing condition requires aggregate cash proceeds from ARYA's trust account and the PIPE Financing to equal no less than $250 million (net of redemptions and transaction expenses).
- Net Tangible Assets: ARYA must maintain at least $5,000,001 in net tangible assets post-closing to satisfy Nasdaq listing requirements.
- Revenue and Profit: The filing text does not provide specific revenue, profit, cash flow, or margin figures for Nautilus or ARYA.
Material Changes and Transaction Structure
The primary material change is the proposed merger of a private biotechnology company (Nautilus) with a publicly traded special purpose acquisition company (ARYA). Key structural elements include:
- Share Exchange: Outstanding Nautilus shares and options will be exchanged for shares and options of the new public entity based on the $900 million valuation.
- Board Composition: The post-transaction board will consist of nine directors, with seven determined by Nautilus, one by the ARYA Sponsor, and one designated by Nautilus acceptable to the Sponsor.
- Lock-Up Agreements: Certain Nautilus shareholders, the ARYA Sponsor, and PIPE investors have entered into lock-up agreements restricting the sale of securities for a specified period post-closing.
Guidance, Risks, and Contingencies
The transaction is subject to several material contingencies and risks:
- Closing Conditions: Approval by ARYA and Nautilus shareholders, effectiveness of the Form S-4 Registration Statement, expiration of the HSR Act waiting period, and Nasdaq listing approval.
- Redemption Risk: The transaction requires a minimum cash threshold of $250 million; significant shareholder redemptions could jeopardize closing if the PIPE and trust funds are insufficient.
- Termination Rights: Either party may terminate the agreement if the transaction is not consummated by August 6, 2021, or if required approvals are not obtained.
- Forward-Looking Statements: Management notes that actual results may differ materially from expectations due to integration challenges, regulatory hurdles, and general economic conditions.
Investor Verification Checklist
- Verify the final number of ARYA shareholder redemptions to ensure the $250 million minimum cash condition is met.
- Confirm the approval status of the Form S-4 Registration Statement and the proxy statement/prospectus.
- Review the definitive proxy statement for details on the $900 million valuation methodology and pro forma capitalization.
- Monitor the timeline for the shareholder vote and the expected closing date in Q2 2021.
- Assess the specific terms of the PIPE Financing and the identity of the participating investors.